Lilly

Lilly 4Q10

4Q Revenues: $6.2 billion (+4%)

4Q Earnings: $1.2 billion (+28%)

FY Revenues: $23.1 billion (+6%)

FY Earnings: $5.1 billion (+17%)

Comments: Sales growth was driven by Cymbalta, +19% for 4Q10 ($985 million) and +13% for FY10 ($3.5 billion), Alimta (+9% / $569 million in 4Q 10, and +29% / $2.2 billion in FY10), and the Animal Health unit (+20% / $424 million in 4Q10, and +15% / $1.4 billion for FY10), which grew partly because of an acquisition. Zyprexa sales fell 2% in 4Q10 to $1.3 billion, due to lower demand. Effient sales were $47 million in 4Q10, up from $36.3 million in the previous quarter.